Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center talks of how he identifies subgroups of…
Browsing: Acute Lymphoblastic Leukemia
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses the date of the RESORCE Trial…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how healthcare professionals are integrating immunotherapy…
Alan P. Venook MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses integrating immunotherapy into existing treatment regimens…
Alan P. Venook, M.D., FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how to integrate immunotherapy into existing…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how checkpoint inhibitors will be used in unresectable HCC treatment…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how targeted therapies seem to work better for patients with…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses regorafenib in clinical practice at the 2017 Gastrointestinal Cancers Symposium…
Thomas A. Abrams, MD of Dana Farber Cancer Institute gives an overview of the results of the RESORCE trial, that…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses new agents for the treatment of advanced HCC at the…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses Gallium 68 versus Low Volume PRRT…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania states that Gallium 68 should be Used…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses how Gallium 68 Provides Much More…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center answers the question Where to Put PRRT in the Treatment Paradigm at…
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses the relationship between Theranostics and Sumaratin Receptors in Neuroendocrine Cells at ASCO…
As part of our ASH 2016 coverage, Dr. John Mascarenhas, from Mount Sinai School of Medicine, joined Patient Power to…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses how Nivolumab Shows Significant Overall Survival Benefit in Metastatic Gastric Cancer…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses the Potential Scenarios for Ramucirumab plus Pembrolizumab at ASCO GI 2017
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses how Gallium 68 Scan has now Become Standard for Staging Neuroendocrine Tumors…
Davendra Sohal, MD of Cleveland Clinic outlines the Pancreatic Cancer Trends for 2017 from ASCO GI 2017
Davendra Sohal, MD of Cleveland Clinic discusses that Improvement in Systemic Therapies are Needed in in Pancreatic Cancer from ASCO…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
Davendra Sohal, MD of Cleveland Clinic presents the Results from Internal Expedience Borderline Resectable Pancreas Cancer at ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering outlines Potential Practicing Changing Data from ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering gives an in depth overview of the data presented at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how healthcare professionals will be integrating immunotherapy into existing treatment regimens…
Howard S. Hochster, MD of Yale Cancer Center discusses the outcomes of the randomized phase 2 study in BRAF-mutated patients…
David Ilson, MD of Memorial Sloan Kettering describes the Advantages of Induction Chemotherapy in Esophageal Cancer at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how genetic profiling has changed the treatment approach for patients with…
Cynthia Sears, MD of Johns Hopkins sees a promising link to Microbiome Study and MSI Colorectal Cancer Immunotherapy. Interviewed at…
Howard S. Hochster, MD of Yale Cancer Center discusses how to use both TAS-102 and Regorafenib in patients with metastatic…
Davendra Sohal, MD of Cleveland Clinic answers the question Will SWOG S1505 Impact Treatment of Pancreatic Cancer at ASCO GI…
Howard S. Hochster, MD of Yale Cancer Center discusses the difference between Regorafenib, 5FU, and TAS-102 at the 2017 Gastrointestinal…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering gives his view on checkpoint inhibitors and their incorporation into treatment for…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his view on reliably identifying subgroups of patients for…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his thoughts on whether or not physicians will start…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on the outcomes of the RESORCE trial,…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on integration of new agents for advanced…
SCCA’s Dr. Ajay Gopal discusses treatment options in lymphoma and chronic lymphocitic leukemia (CLL), as well as the strength of…
Nevena Damjanov, MD of University of Pennsylvania talks about how checkpoint inhibitors will be incorporated into unresectable HCC treatment at…
Nevena Damjanov, MD of University of Pennsylvania discusses how healthcare professionals can reliably identify subgroups of patients for targeted therapies…
Nevena Damjanov, MD of University of Pennsylvania discusses how regorafenib will be incorporated into clinical practice at 2017 Gastrointestinal Cancers…
Nevena Damjanov, MD of University of Pennsylvania gives an overview of the outcomes of the RESORCE Trial that were presented…
Nevena Damjanov, MD of University of Pennsylvania discusses how new agents being studied for advanced HCC will be integrated into…
David Ilson, MD of Memoral Sloan Kettering Cancer Center discusses data released at ASCO GI 2017. A total of 198…
Cynthia Sears, MD of John Hopkins University School of Medicine highlights there is Accumulating evidence that the microbiome may play…